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Abstract
Background: Thymoma is a heterogeneous group of tumors in biology and clinical behavior. Even
though thymoma is divided into five subgroups following the World Health Organization
classification, the nature of the disease is mixed within the subgroups.
Results: We investigated the molecular characteristics of genetic changes variation of thymoma
using cDNA microarray based-comparative genomic hybridization (CGH) with a 17 K cDNA
microarray in an indirect, sex-matched design. Genomic DNA from the paraffin embedded 39
thymoma tissues (A 6, AB 11, B1 7, B2 7, B3 8) labeled with Cy-3 was co-hybridized with the
reference placenta gDNA labeled with Cy-5. Using the CAMVS software, we investigated the
deletions on chromosomes 1, 2, 3, 4, 5, 6, 8, 12, 13 and 18 throughout the thymoma. Then, we
evaluated the genetic variations of thymoma based on the subgroups and the clinical behavior. First,
the 36 significant genes differentiating five subgroups were selected by Significance Analysis of
Microarray. Based on these genes, type AB was suggested to be heterogeneous at the molecular
level as well as histologically. Next, we observed that the thymoma was divided into A, B (1, 2) and
B3 subgroups with 33 significant genes. In addition, we selected 70 genes differentiating types A and
B3, which differ largely in clinical behaviors. Finally, the 11 heterogeneous AB subtypes were able
to correctly assign into A and B (1, 2) types based on their genetic characteristics.
Conclusion: In our study, we observed the genome-wide chromosomal aberrations of thymoma
and identified significant gene sets with genetic variations related to thymoma subgroups, which
might provide useful information for thymoma pathobiology.
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Background
Thymoma is a thymic epithelial cell tumor having organ-
otypic features and no overt cytologic atypia. Although
controversy still remains, the classical histological classifi-
cations of thymoma based on the proportion of reactive
lymphocytes and tumor epithelial cells have been
replaced by a histogenetic classification that basically sub-
divides thymoma into medullary, cortical, and mixed
types, according to cytological features of epithelial cells
[1-5]. Several studies supported the validity of the histoge-
netic classification and the World Health Organization
(WHO) classification adopted five subtypes of thymoma
stratified in histogenetic classification [6-9]. The histolog-
ical subtypes in the WHO classification have been
reported to have independent prognostic significance,
and types A and AB demonstrate indolent biological
behavior compared with type B [6-8]. Several studies have
tried to demonstrate the underlying pathogenetic mecha-
nisms to explain the different biological behaviors of thy-
moma, according to the histological subtype and stages by
applying several markers, but no conclusive results have
been demonstrated yet [10-18].
A recent report on genetic alterations of thymoma using
comparative genomic hybridization (CGH) and fluores-
cent in situ hybridization methods demonstrated that
type B3 thymoma frequently occurred with losses of chro-
mosomes 6, 13 q, 16 q and gains of chromosome 1 q,
while type A thymoma rarely showed cytogenetic abnor-
malities [19]. Subsequent studies by the same group
based on loss of heterozygosity (LOH) analyses inferred
two different genetic pathways of tumorigenesis of thy-
moma, and heterogeneous genetic alterations in subtypes
of thymoma, excluding type A, were identified by CGH
and LOH analyses [20,21]. However, a recent CGH study
identified several new chromosomal imbalances even in a
significant proportion of type A thymomas [22].
The application of DNA microarray technology has pro-
vided us a high-throughput evaluation of the whole
genome as well as significant genetic information at a sin-
gle gene level and has enabled us to classify different neo-
plasms based on the characteristic genetic patterns. So far
there has been no report focusing on differences of genetic
alterations between subtypes of thymoma using a cDNA
microarray based-CGH method (microarray-CGH). In
our study, genetic alterations of all WHO-defined sub-
types of thymoma were investigated using high resolution
microarray-CGH followed by hierarchical cluster analyses
of the data to identify specific patterns of genetic aberra-
tions and genes associated with each subtype.
Results
Chromosome analysis of thymoma
For evaluating the pattern of genetic aberration of thy-
moma, 13,248 unique genes were obtained after preproc-
essing, of which 8,411 were mapped by SOURCE.
Commonly amplified or deleted regions were identified
by averaging the log2 ratio values of each gene from 39
thymoma patients, plotted on the location of the chromo-
somes using the Chromosome Analyzer and Map Viewer
using S-plus (CAMVS) (Figure 1A). When we evaluated
overall chromosome patterns based on the cut-off value of
± 0.3, deletions in chromosomes 1, 2, 3, 4, 5, 6, 8, 12, 13
and 18 were identified.
Subtype specific analysis demonstrated losses of chromo-
somes 2, 4, 6q, and 13, identified in type A (Figure 1B),
and losses of chromosomes 1p, 2q, 3q, 4, 5, 6q, 8, 13, and
18 and a gain of chromosome 9q were identified in type
B1 (Figure 1C). Type B2 demonstrated losses of chromo-
somes 1p, 2q, 3q, 4, 5, 6q, 8, 13, and 18 (Figure 2A), and
type B3 revealed chromosome 2q, 4, 5, 6, 8, 12q, 13, and
18 losses, and chromosome 1q gain (Figure 2B). Type A
therefore demonstrated the least degree of chromosomal
abnormality while subtypes of type B thymoma showed
overlapping pattern losses in many chromosomes. Chro-
mosome 9q gain was identified only in type B1 thymoma,
while chromosome 1q gain was present only in type B3
thymoma. Meanwhile, type AB showed the losses of chro-
mosomes 2, 4, 5, 6q, 8, 13 and 18 (Figure 2C). In addi-
tion, losses of chromosomes 2, 4, 6, and 13 were observed
in all subtypes.
Overall genetic pattern analysis
To investigate the genetic differences of five subtypes of
thymoma, we selected 36 distinctive genes at a false dis-
covery rate (FDR) of 2.5% by multi-class SAM (23) (Addi-
tional file 1). Supervised hierarchical clustering of 39
cases of thymoma microarray-CGH data with the selected
36 genes demonstrated that types A and B were separately
clustered (Figure 3). However, types B1, B2 and B3
branches were intermingled with each other. In addition,
eight samples of type AB were dispersed in various B
branches, and three samples of type AB were included in
type A. These results suggest that type AB has combined
characteristics of types A and B, genetically (Figure 3).
Hence, type AB was excluded from further analyses to
diminish error rate in understanding the genetic charac-
teristics of thymoma subtypes. Among the 36 selected
genes, 16 are ESTs with unknown functions and six are
located in the 1q region. Cervical cancer oncogene-4
(HCC-4, 2q24.2) was amplified in all subtypes except for
type B1. T-cell receptor gamma locus (TARP, 7p15-p14)
was deleted in all subtypes except for type A (AB: 63%, B1:
33%, B2: 50%, B3: 12.5%).BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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Microarray-CGH profiles using CAMVS (Chromosome analyzer and Map Viewer using S plus) Figure 1
Microarray-CGH profiles using CAMVS (Chromosome analyzer and Map Viewer using S plus). Each black line displays the 
overall genetic pattern of each thymoma patient and the central orange horizontal line represents the common genetic altera-
tions of 8,411 genes in all patients. (A) Overall microarray-CGH profile of 39 thymoma patients showing the losses on chro-
mosomes 1, 2, 3, 4, 5, 6, 8, 12, 13 and 18. (B) The common genetic alteration patterns in type A with losses of chromosomes 
2, 4, 6q, and 13. (C) The common genetic alteration patterns in type B1 with losses of chromosomes 1p, 2q, 3q, 4, 5, 6q, 8, 13, 
and 18 and a gain of chromosome 9q.BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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(A) The common genetic alteration patterns in type B2 with losses of chromosomes 1p, 2q, 3q, 4, 5, 6q, 8, 13, and 18 Figure 2
(A) The common genetic alteration patterns in type B2 with losses of chromosomes 1p, 2q, 3q, 4, 5, 6q, 8, 13, and 18. (B) The 
common genetic alteration patterns in type B3 with losses of chromosomes 2q, 4, 5, 6, 8, 12q, 13, 18 and a gain of chromo-
some 1q. (C) The common genetic alteration patterns in type AB with losses of chromosomes 2, 4, 5, 6q, 8, 13 and 18.BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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Comparison of genetic aberration patterns between 
subtypes of thymoma
A) Comparison between type A and type B
SAM was performed with types A and B in order to iden-
tify genetic alterations distinguishing tumors composed
of medullary and cortical epithelium. We selected 50
genes at a FDR of 1.7%, and the hierarchical clustering
showed the clear separation of type A and type B (Figure
4-A, Additional file 2). Small branch pattern analyses
showed more similarity between type B1 and type B2 than
between type B2 and type B3, and some similarity
between type A and type B3. Among the 50 genes selected,
chromosomes 1 and 5 included 10% each (5/50), and
chromosomes 6, 11, 13 and 17 each included 6% (3/50).
We observed that these genes were closely located within
each chromosome, suggesting the possible fragmental
losses of thymoma chromosomes. For example, three
genes were located nearby on 1p31, and four genes were
located nearby on the 5q arm. Among the genes on chro-
mosome 1, FLJ20489 (10/22), 15 KDa selenoprotein
(SEP15, 1p 31, 6/22), leptin receptor gene related protein
(LEPR, 1p 31, 7/22), and phosphatidylinositol glycan,
class K (PIGK, 1p 31, 11/22), were frequently deleted in
cortical subtypes.
Genetic pattern profiles of thymoma subgroups by the hierarchical clustering of 36 selected genes Figure 3
Genetic pattern profiles of thymoma subgroups by the hierarchical clustering of 36 selected genes. Color scale bar showing the 
level of log R/G ratio. The thymoma subgroup of each patient is displayed in a different color as below.BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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Comparison of genetic aberration patterns between subtypes of thymoma Figure 4
Comparison of genetic aberration patterns between subtypes of thymoma. (A) Hierarchical clustering with 50 selected genes 
showing different genetic patterns between types A and B (1, 2, 3). (B) Hierarchical clustering of 70 genes showing different 
genetic patterns in types A and B3. (C) Hierarchical clustering of 48 genes showing the different genetic patterns between 
types B (1, 2) and B3. (D) Hierarchical clustering with 33 genes showing three molecular characteristic subgroups of thymoma 
as types A, B(1,2) and B3.BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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B) Comparison between type A and type B3
SAM was performed with types A and B3 in order to iden-
tify genetic alterations responsible for the markedly differ-
ent biologic behaviors of types A and B3. Seventy genes
with different copy numbers were selected with a FDR of
1.2%, and the cluster analysis using these 70 genes
showed clear separation between type A and type B3 (Fig-
ure 4-B, Table 1). Gains of these genes were prevalent in
type A while losses were prevalent in type B3. Twenty-five
of the 70 genes were ESTs, and 12 genes were located on
chromosome 6, most of which were concentrated on the
6p21.3-6p25 regions. In type B3, frequent deletions were
observed in chromosome 6 open reading frame 10
(C6orf10, 6p21.3), butyrophilin subfamily 3, member A2
(BTN3A2, 6p22.1), and thiopurine s-methyltransferase
(TPMT, 6p22.3), with a frequency of 75% (6/8), 87.5%
(7/8), 75% (6/8), respectively. All the selected genes on
chromosome 5 were on the 5q arm, and we observed that
cervical cancer oncogene 4 (HCC-4, 2q24.2) was more
amplified in all type A cases than type B3 cases.
C) Comparison of cortical subtypes
Based on the previous results demonstrating that among
cortical subtypes, the pattern of small branches showed
more similarity between types B1 and B2 than types B2
and B3, we divided cortical subtypes into types B1+B2 and
B3 for evaluating genetic alterations. We selected 48 sig-
nificant genes with a FDR of 11% by SAM (Figure 4-C,
Additional file 3). As the FDR value of differential gene
selection is relatively high, type B1+B2 and type B3 were
not clustered clearly, but they showed a tendency of sepa-
ration. Twenty-nine of 48 selected genes were on chromo-
some 1, and nine of them were ESTs. Among the 29 genes
on chromosome 1, 26 (86%, 26/29) were amplified in
type B3 type, while only four (13%, 4/29) were amplified
in type B1+2. The selected genes were concentrated in the
1q32 and 1q42-q43 regions.
D) Comparison between type A, type B 1+2, and type B3
SAM was carried out with three subgroups of types A,
B1+B2, B3, and 33 significant genes were selected at 2.6%
FDR, most of which are located on chromosomes 1 and 6
(Table 2). When a clustering analysis was carried out with
these 33 genes (Figure 4-D), type A was clearly separated
from types B1+2 and B3.
Twelve of the selected 33 genes were ESTs, with six genes
on chromosome 1. Four genes located on 1q, chromo-
some 1 open reading frame 21 (C1orf21), putative DNA/
chromatin binding motif (PLU-1), protein phophatase1
regulator subunit 12B (PPP1R12B), and SEC22 vesicle
trafficking protein-like 1 (SEC22L1) were amplified only
in type B3.
E) Prediction analysis of thymoma subtypes
Based on the previous results, thymoma could be divided
into three genetically distinct subgroups (types A, B1+B2,
and B3) and genetically heterogeneous type AB. Predic-
tion Analysis of Microarray (PAM) (24) as in the method
was carried out to predict to which subgroup type AB
belongs. To equilibrate each group, the training set evenly
included six cases from types A, B1+2, and B3. Eleven
cases of type AB were used as a test set in the prediction
analysis. The cross-validation of the selected 44 subgroup
classifier genes showed 100% accuracy with types A and
B1+B2 and 50% accuracy with type B3 in the training set
(Figure 5-A). The prediction analysis demonstrated that
among the 11 cases of type AB, three cases were classified
into type A, and the remaining eight cases into type B (1,
2) (Figure 5-B), which is coherent with the dendrogram in
Figure 3.
Discussion
A number of study results on systemic genetic analyses of
thymoma have been reported in the past few years after a
few case reports on the chromosomal abnormalities of
thymoma [19-22], [25-27]. Zettl et al. demonstrated for
the first time recurrent chromosomal imbalances in type
B3 thymoma with CGH and FISH methods [19]. They
identified 16 cases of type B3 that showed chromosomal
gains (1q, Xq, and 8p12) and losses (6 and 13q), while 12
cases of type A did not reveal any chromosomal abnor-
malities, with the exception of one case with a partial loss
of 6p. Subsequently, the same group, using CGH and mic-
rosatellite analyses, inferred two pathways of thymoma
tumorigenesis by demonstrating that type A (3/8 cases)
presented with consistent LOH in the region 6p23.3-25.5
only, while type B3 revealed various aberrations such as
APC on chromosome 5q21 (3/14 cases), RB on 13q14 (5/
14 cases), and p53 gene on 17p13.1 (4/14 cases) loci, as
well as LOH in the region 6p23.3-25.5 (5/14 cases) [20].
They expanded their samples to include types AB and B2
in addition to types A and B3 by using laser-assisted
microdissection or short-term thymic epithelial tumor
cell cultures and found that 1) the various WHO-defined
subtypes of thymoma exhibited different profiles of
genetic alterations, 2) only type A was genetically homo-
geneous with abnormalities mainly involving chromo-
some 6 while other subtypes showed genetic
heterogeneity, and 3) some cases of type B2 were geneti-
cally closely related to type B3, and might arise from this
type by gain of genetic aberrations [21]. In addition, Pen-
zel et al [22] reported a main cluster characterized by a
gain of 1q and losses of 6q and 16q occurring only in type
B3 (3/4 cases). Three of eight cases of type A thymoma
demonstrated various types of chromosomal imbalances
in contrast to the study results reported by Zetti et al [19].
Namely, the results of the CGH studies on thymoma by
two groups demonstrated some discrepancies [19-22].BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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Table 1: List of distinctive 70 genes between types A and B 3
ID Symbol Cytoband Name type A type B3
gain loss gain loss
AA186327 SNX14 6q14-q15 sorting nexin 14 (5/8)
AA458945 RAB30 11q12-q14 RAB30, member RAS oncogene family (5/6) (4/8)
AI201652 EST (4/6) (1/8) (3/8)
AI337344 HSRG1 16q23.1 HSV-1 stimulation-related gene 1 (6/6) (3/8) (1/8)
AA991868 EST (6/6) (3/8) (2/8)
AA465687 HCC-4 2q24.2 cervical cancer oncogene 4 (6/6) (2/8) (4/8)
AI493835 ESTs (6/6) (2/8) (1/8)
AW087220 ESTs (4/6)
AA478436 SMARCD2 17q23-q24 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 2
(6/6) (2/8)
AI015542 TG737 13q12.1 Probe hTg737 (5/6) (2/8)
AI733279 ESTs (6/6) (2/8) (4/8)
AA973681 ESTs (3/6)
N93021 TBCA 5q14.1 (5/8)
AA917489 ESTs (6/6)
AA775364 RPL30 8q22 ribosomal protein L30 (1/6)
AA987488 ESTs (2/6) (2/8)
AA478585 BTN3A3 6p22.1 butyrophilin, subfamily 3, member A3 (1/6) (2/8)
AI291184 OCLN 5q13.1 occludin (5/6) (2/8)
AI348521 HBS1L 6q23-q24 HBS1-like (6/8)
AA287917 TNPO1 5q13.2 karyopherin (importin) beta 2 (2/6) (2/8)
AA885609 MAP1A 15q13-
qter
microtubule-associated protein 1A (8/8)
AI375415 ESTs (2/8)
AA489670 ESTs (3/8)
AI972677 MSMB 10q11.2 microseminoprotein, beta- (1/6) (1/6)
N71628 SPIB 19q13.3-
q13.4
Spi-B transcription factor (Spi-1/PU.1 related) (3/5) (1/6)
AI383789 ESTs
AI261862 ESTs (2/6) (3/8)
AI985214 TFPI 2q31-
q32.1
tissue factor pathway (2/6)
H17513 HSPA1L 6p21.3 heat shock 70kDa protein 1-like (2/8)
T61428 NEDD9 6p25-p24 neural precursor cell expressed, developmentally down-regulated 9 (2/6) (2/8)
N90109 NCL 2q12-qter nucleolin (3/6) (1/8)
AI972568 RPL36A Xq22.1 ribosomal protein L36a (3/6)
AA442092 CTNNB1 3p21 catenin, beta 1, 88 kDa (1/8)
AA902196 ESTs (2/6) (1/8)
AW009090 NDUFB3 2q31.3 NADH dehydrogenase 1 beta subcomplex, 3, 12 kDa (1/8)
AA975250 MAT2B 5q34-
q35.1
methionine adenosyltransferase II, beta (3/8)
AI281237 C13orf12 13q12.3 chromosome 13 open reading frame 12 (3/8)
H51066 OBRGRP 1p31.3 leptin receptor gene-related protein (2/8)
AA465386 DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 (3/8)
AI951501 RPL12 9q34 ribosomal protein L12 (6/6) (1/8)
AW075424 SFRS3 6p21 splicing factor, arginine/serine-rich 3 (6/6) (1/8)
AI086414 EST (2/8)
AI279626 EST (2/8)
AA677257 TPMT 6p22.3 thiopurine S-methyltransferase (6/8)
AA887201 C13orf1 13q14 chromosome 13 open reading frame 1 (1/8)
AI284218 ESTs (2/6) (1/8)
AA991871 FOXA1 14q12-q13 forkhead box A1 (3/6)
AA864434 ESTs (4/6) (1/8) (1/8)
AI318162 FLJ14936 1p33-
p32.1
hypothetical protein FLJ14936 (1/8)
AA504351 ZNF146 zinc finger protein 146 (1/6) (6/8)
AI302566 ESTs (3/6) (1/8)BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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We used cDNA microarray based-CGH to investigate the
genome-wide genetic aberrations of thymoma. In contrast
to CGH and LOH analyses, cDNA microarray based-CGH
could provide us a high-throughput evaluation of the
whole genome and also with significant genetic informa-
tion at a single gene level. The other advantages of using
microarray-CGH are the utility of paraffin embedded tis-
sue DNA, the requirement of a small amount of genomic
DNA and the possible direct comparison with RNA
expression. With this technique there was no need to
amplify the DNA in order to obtain the genetic informa-
tion of more than 10,000 genes, which sometimes may
blur the results. Compared to RNA expression analysis, for
which we need the fresh, well-stored tissue samples (the
major limitation of tissue procurement), using the paraf-
fin embedded tissues allowed us to do the retrospective
studies using a large number of samples.
The main purpose of our study was to identify differential
genetic patterns to explain distinct morphologic findings
and different biologic behaviors, according to subtypes of
thymoma. For this, we included all WHO-defined sub-
types of thymoma for genetic analysis, as in the previous
reports [25-29]. The previous studies using CGH and mic-
rosatellite analyses excluded subtypes with large numbers
of lymphocytes (type AB, B1, and B2) from the samples
because CGH analyses generally require a tumor cell con-
tent of more than 50% [19,20]. As we consider the clinico-
pathological behavior of thymoma comes from the
complex biology with thymic spindle epithelial cells and
surrounding microenvironment including lymphocytes.
Hence, to understand the phenotypic biology of thy-
moma, whole tissues were used for genetic evaluation in
this study. The results from the current data might support
in-depth understanding of tumor biology with more clin-
ically relevant information, resulting in potential clini-
cally useful biomarker candidates for subtype
classification. However, the careful explanation is needed
for understanding pathogenesis of thymoma concerning
the influence from the lymphocytes.
The CAMVS, which was developed in our institute for the
effective analysis and visualization of microarray-CGH
results, was used to identify the significant genetic aberra-
tions of thymoma. Chromosomal deletions in chromo-
somes 1, 2, 3, 4, 5, 6, 8, 12, 13 and 18 were observed by
the comparison of the mean log2 ratio after microarray-
CGH of a total of 39 cases, suggesting the characteristic
genetic aberrations of thymoma. The chromosome 6 loci,
known to possess many tumor suppressor genes, well-
established deletion sites in thymoma such as 6q21,
6q23, and 6q25-27, and the genes selected in our study,
were also frequently located on 6q, confirming the previ-
ous data [29].
Subtype specific analyses demonstrated that losses of
chromosomes 2, 4, 6, and 13 were identified in all sub-
types of thymoma. Type A thymoma had the least number
of chromosomal abnormalities while type B had many
more chromosomal abnormalities in accordance with the
previously reported data [19-22]. Thymoma type B
revealed increased genetic aberrations suggesting a rup-
ture in chromosomal stability, and these findings corre-
late well with the indolent biological behavior of type A
AI311303 ESTs (3/8)
AW078798 UBB 17p12-
p11.2
ubiquitin B (6/6) (2/6)
AA927666 ARCH 1p35.1 archease (3/6) (1/8)
AA426027 SNX3 6q21 sorting nexin 3 (3/6) (6/8)
AI262055 ESTs (1/8)
AA936514 C6orf10 6p21.3 chromosome 6 open reading frame 10 (1/6) (6/8)
AI364310 ESTs (5/6)
AA504141 UBE2J1 6q15 ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) (1/8)
AA130187 WT1 11p13 Wilms tumor 1 (1/6)
N56693 COX7B Xq21.1 cytochrome c oxidase subunit VIIb (5/6) (1/8)
AA401441 BF 6p21.3 B-factor, properdin (1/8)
AA917821 MRPS30 5q11 mitochondrial ribosomal protein S30 (1/6)
AI431827 ESTs (4/8)
AA935697 ESTs (3/8)
AI248605 BTN3A2 6p22.1 butyrophilin, subfamily 3, member A2 (7/8)
AI206970 ESTs
AW058415 HBXIP 1p13.3 hepatitis B virus × interacting protein (2/6)
N69107 YWHAH 22q12.3 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, eta polypeptide
(1/6)
AA863025 ESTs (2/6)
The ID indicate GeneBank ID and the symbol and the cytoband information are from their SOURCE http://source.stanford.edu. The incidence is 
the number oh cases having log2 ratio in the range of our criteria ± 0.3. ESTs are expressed sequenced tags, clones of unknown functions. Genes 
are listed according to order FDR values.
Table 1: List of distinctive 70 genes between types A and B 3 (Continued)BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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and the aggressive behavior of type B. Although a loss of
chromosome 6q had been reported as the only chromo-
somal abnormality in a rare case of type A thymoma, a
recent report by Penzel et al [22] identified various types
of chromosome gains such as 1q, 9q, 16, 17, 20, and 22
and losses such as 2q, 4q, 5q, 6q, 9p, and 13q in three out
of eight cases of type A analyzed. We also identified losses
of chromosomes 2, 4, 6q, and 13 in type A. So the results
of our study support the genetic heterogeneity in a signif-
icant proportion of type A, although genetic aberrations
were usually less prominent, as compared with type B.
Furthermore, type B demonstrated heterogeneous and
overlapping chromosomal aberrations in our study.
Losses of chromosomes 1p, 2q, 3q, 4, 5, 6q, 8, 13, and 18
and a gain of chromosome 9q were identified in type B1.
Type B2 demonstrated losses of chromosomes 1p, 2q, 3q,
4, 5, 6q, 8, 13, and 18 and type B3 revealed chromosome
2q, 4, 5, 6, 8, 12q, 13, 18 losses and chromosome 1q gain.
We could confirm the type B3 specific 1q gain and losses
of 6, 13, and 16 in all three cortical subtypes, as in previ-
ous reports [19-22]. However, losses of chromosomes 2q,
4, 5, 8, 13 and 18 were also identified in all three cortical
subtypes. So our results also confirm the presence of vari-
ous other overlapping chromosomal abnormalities in
three cortical subtypes in addition to well established B3
specific 1q gain and chromosome 6, 13, and 16 losses.
Furthermore, we identified chromosomal abnormalities
Table 2: List of distinctive 33 genes among types A, B (1, 2) and B3
ID Symbol Cytoband Name type A type B (1,2) type B3
gain loss gain loss gain loss
AA186327 SNX14 6q14-q15 sorting nexin 14 (1/14) (5/8)
AA287917 TNPO1 5q13.2 karyopherin (importin) beta 2 (4/6) (1/14) (2/8)
AA442092 CTNNB1 3p21 catenin, beta 1 (1/14) (1/8)
AA455917 SEC22L1 1q21.2-q21.3 SEC22 vesicle trafficking protein-like 1 (2/6) (8/14) (2/8) (1/8)
AA458945 RAB30 11q12-q14 RAB30, member RAS oncogene family (5/6) (10/14) (4/8)
AA465386 DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 (4/14) (3/8)
AA465687 RBMS1 2q23.2 cervical cancer oncogene 4 (6/6) (2/14) (7/14) (2/8) (4/8)
AA478436 SMARCD2 17q23-q24 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily d, 
member 2
(6/6) (3/14) (6/14) (1/8) (2/8)
AA478585 BTN3A3 6p21.3 butyrophilin, subfamily 3, member A3 (1/6) (1/8)
AA774608 PPP1R12B 1q32.1 protein phosphatase 1, regulatory (inhibitor) 
subunit 12B
(1/8)
AA931882 ESTs (3/14) (5/8)
AA973568 ESTs (6/6) (1/14) (9/14) (2/8) (4/8)
AA973681 ESTs (5/6) (3/14) (1/8)
AA991868 ESTs (6/6) (2/14) (7/14) (3/8) (1/8)
AA991871 FOXA1 14q12-q13 forkhead box A1 (3/6) (1/14) (3/8)
AI001856 ESTs BRG1-binding protein ELD/OSA1 (2/6) (6/14) (2/8)
AI015542 TTC10 13q12.1 Probe hTg737 (5/6) (10/14) (2/8) (1/8)
AI201652 ESTs (5/6) (7/14) (1/8) (3/8)
AI261862 ESTs (2/6) (12/14) (3/8)
AI289196 MAN1A2 1p13 mannosidase, alpha, class 1A, member 2 (3/6)
AI291184 OCLN 5q13.1 occludin (5/6) (2/14) (1/14) (1/8)
AI300984 ESTs (1/6) (2/14)
AI311303 ESTs (9/14) (3/8)
AI335359 C1orf21 1q25 chromosome 1 open reading frame 21 (3/8)
AI337344 HSRG1 16q23.1 HSV-1 stimulation-related gene 1 (6/6) (1/14) (8/14) (3/8) (2/8)
AI348521 HBS1L 6q23-q24 HBS1-like (8/14) (6/8)
AI392929 PLU-1 1q32.1 putative DNA/chromatin binding motif (1/8)
AI401608 ESTs (2/8)
AI492063 ESTs (2/6) (1/14) (3/14) (5/8)
AI493835 ESTs (6/6) (1/14) (4/14) (2/8) (1/8)
AI655101 XPR1 1q25.1 xenotropic and polytropic retrovirus receptor (1/14) (1/14) (4/8)
AI972955 TARP 7p15-p14 T cell receptor gamma locus (1/6) (7/14)
H99842 EIF5A 17p13-p12 eukaryotic translation initiation factor 5A (2/6)
The ID indicate GeneBank ID and the symbol and the cytoband information are from their SOURCE http://source.stanford.edu. The incidence is the 
number oh cases having log2ratio in the range of our criteria ± 0.3. ESTs are expressed sequenced tags, clones of unknown functions. Genes are 
listed according to order FDR values.BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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Prediction analysis of thymoma subgroups Figure 5
Prediction analysis of thymoma subgroups. (A) Cross-validated probabilities of the selected 136–44 genes at threshold 2.78 in 
the training set using 18 cases of thymoma subgroups, six cases each of A, B (1, 2), B3, showing 90% accuracy. (B) Prediction 
analysis of 11 ambiguous type AB samples as a training set showed the similar result as Figure 2, designating three as type A and 
eight as type B.BMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
Page 12 of 15
(page number not for citation purposes)
of type B1 for the first time. Type B1 shared a similar pat-
tern of chromosome losses with B2 but showed a 9q gain,
which was identified only in type B1. These diverse
genetic variations in our data support the underlying
genetic influence on the biology of thymoma subtypes,
resulting in various clinical behaviors.
After the systematic insight into genetic aberrations of thy-
moma was achieved according to molecular characteris-
tics, the types were dissected into genetically related
subgroups for further detailed analyses. First, we identi-
fied that type AB is genetically heterogeneous, so we
excluded type AB for further analyses. Then, we identified
that type A was distinct from type B, based on the molec-
ular characteristics.
The cortical subtypes did not demonstrate clear separation
by hierarchical clustering analysis. Among cortical sub-
types, type B1 morphologically maintains distinct cortico-
medullary differentiation with indistinct tumor epithelial
cells and usually shows indolent biologic behavior, as
compared with types B2 and B3. Type B2, which definitely
shows more aggressive biologic behavior than type B1,
has more prominent tumor epithelial cells than type B1
and gray zones are sometimes present between type B2
and B3 histologically. Furthermore, tumors having both
type B2 and B3 areas are commonly present. So we
expected genetic similarities between type B2 and type B3.
However the pattern of small branches showed more sim-
ilarities between types B1 and B2 than between types B2
and B3.
Based on the hierarchical clustering analysis, we could
assume that thymoma could be divided into four geneti-
cally different subgroup of types A, AB, B1+2, and B3. We
tried to assign 11 genetically heterogeneous cases of type
AB into types A and B using the prediction analysis. The
prediction analysis results were coherent with the cluster-
ing analysis results, showing that three clustered in type A
were predicted to be type A, and eight clustered in type B
were designated as type B. Type AB was reported to be
genetically more heterogeneous than type A and some
chromosomal aberrations characteristic of type B were
reported to be present in type AB [21,22]. Type AB is
defined as an organotypic thymoma, showing both fea-
tures of medullary and cortical thymoma. In fact, there is
a wide morphologic spectrum in type AB. Some show a
distinct nesting of spindled epithelium as in the Regard
type of nasopharyngeal carcinoma, while in others, epi-
thelial cells are sprinkled individually as in the Schmincke
type of nasopharyngeal carcinoma.
The WHO classification of thymoma is reported to be
associated with the invasiveness and recurrence of thy-
moma. Among the various gene sets, the 70 genes distin-
guishing types A and B3 might be related to the
malignancy of thymoma, because B3 is the typical malig-
nant tumor with a metastatic property among 5 subtypes.
Among the 70 genes, the significant number of genes were
related to cell structure and adhesion. NEDD9 (T61428,
neural precursor cell expressed developmentally down
regulating 9) and CTNNB (AA442092, cadherin-associ-
ated protein beta 1), which are known to be the adhesion-
related genes, were deleted in type B3, suggesting
increased cell motility for metastasis. As Penzel et al.
reported the genetic amplification in chromosome 1 in
malignant type B2 and B3, frequently amplified genes
chromosome 1 were observed in B3 [22].
There have been no standard methods to detect the signif-
icant genes among the distinct groups in microarray-
CGH. Several reports mentioned the correlation of the
CGH and expression profiling suggesting the possibility
of using similar approach for both in selecting the signifi-
cant genes [33,34]. Among the several analytic methods
for gene expression profiling, SAM method has been used
as one of the standard methods based on the t-test. There-
fore, SAM method is applied in this investigation.
Recently, a few reports suggest new methods to detect
numbers of significant genes between distinct groups in
microarray-CGH [35,36]. As there is no valid method to
analyze differentially gained or lost genes in microarrya-
CGH, more appropriate method with biological valida-
tion should be evaluated.
Only one concern of this study is the limited numbers of
the samples in each type. Especially with the microarray-
CGH, which could evaluate thousands of genes simulta-
neously, the sample size is the significant matter. To over-
come the over-fitting problem, one effort is to divide the
samples into the training and the independent test set.
However, the sample size is not large enough to select the
genes based on this approach, requiring us to apply the
cross-validation method in the same training set. As all
these efforts to define the subgroups based on the clinico-
pathologic or molecular level result from the lack of good
prognostic markers and treatment strategies of thymoma,
the capacity of prediction of current proposed genes sets
needs to be validated in more samples prospectively in
accordance with the clinical parameters.
Conclusion
In this study, we evaluated the genetic characteristics of
the WHO-defined five subtypes of thymoma using micro-
array-CGH. We observed that thymoma could be divided
into four genetically distinct groups of A, AB, B1+2, and
B3. Type AB was determined to be genetically heterogene-
ous in morphology. We identified sets of genes which
characterize the molecular subgroups for the basis of
understanding thymoma biology and the candidateBMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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biomarkers of each group. In conclusion, this study pro-
vides significant information on the genetic background
of thymoma for classification purposes.
Methods
Patients
Thirty-nine cases of thymoma tissue samples (A : 6, AB :
11, B1 : 7, B2 : 7, B3 : 8) were obtained as paraffin embed-
ded tissue blocks from the files of the Department of
Pathology at the Severance Hospital, Yonsei University
College of Medicine. The median age of patients at diag-
nosis was 50 years (range 26–71 years), and the male ver-
sus female ratio was 23:16.
DNA preparation
Ten serial 10 µm thick tissue sections were cut from repre-
sentative paraffin blocks for genomic DNA extraction. The
pathologist (Professor Yang WI) confirmed the diagnoses
and subtypes according to the WHO classification (9),
and localized tumor areas in the corresponding hematox-
ylin-eosin (H&E) stained tissue section. Fresh normal pla-
cental tissues from healthy newborns were snap-frozen
for reference samples. Genomic DNA extraction from the
slide was performed according to the conventional proto-
col[30]. Briefly, scraped tissue from the slides was depar-
affinized by washing it twice with 1 µl of xylene at 55°C
for five minutes. After two washes with 100% ethanol, the
samples were dried for two hours at 50°C. The tissues for
reference samples were incubated with 400 µl of DNA
lysis buffer [10 mM Tris pH 7.6, 10 mM EDTA, 50 mM
NaCl, 0.2% SDS, 200 µg/ml Proteinase K] at 42°C for 12
to -24 hours. The incubated products were treated with
the same amount of phenol/chloroform/isoamylalcohol
(Gibco-BRL, Gaithersburg, MD, USA) to isolate the
nucleic acid from the proteins. The DNA was precipitated
with 100% ethyl alcohol containing a 1/3 volume of 10 M
ammonium acetate and 2 µl of glycogen. After being
rinsed with 70% ethyl alcohol, the DNA was dried at
room temperature and then dissolved in ultra-pure water.
The quantity and quality of the DNA were evaluated using
the Gene Spec III (Hitachi, Japan) and the Gel Documen-
tation-Photo System (Vilber Lourmat, France).
cDNA microarray based – CGH (Microarray-CGH)
In this study, we used 17K cDNA microarrays (CMRC-
GenomicTree, Daejeon, Korea) that included 15,720
unique genes. Of these genes, 11,552 were mapped by
SOURCE, a web based database provided by the Genetics
Department of Stanford University [37]. Microarray-CGH
experiments were performed with the indirect design to
determine the genome-wide genetic aberrations in thy-
moma subtypes using sex-matched placental tissue as a
reference. Labeling of DNA was performed following the
institutional protocol as described previously [30,31].
Briefly, four µg of placenta and thymoma tissue DNA were
fluorescently labeled with Cy3 or Cy5-dUTP (Dupont
NEN Life Sciences, Boston, MA, USA), respectively, using
BioPrime DNA Labeling System (Invitrogen, Carlsbad,
CA, USA). Labeled products were purified with a PCR
Purification Kit (Qiagen, Dusseldorf, Germany) and com-
bined with 30 µg of human Cot-1 DNA (Gibco BRL,
Gaitherburg, MD, USA), 100 µg of yeast tRNA (Gibco
BRL, Gaitherburg, MD, USA) and 20 µg of poly(dA-dT)
(Sigma, Saint Louis, MO, USA). Then, the hybridization
mixture was concentrated using a Micro-con 30 (Milli-
pore, Bedford, MA, USA) and hybridized to the 17K cDNA
microarray at 65°C for 16 to18 hours. After washing, the
microarray was scanned using GenePix 4000B (Axon Inc,
Foster, CA, USA). The microarray data was obtained by
GenePix Pro 4.1 software (Axon Inc, Foster, CA, USA).
Data Analysis
Raw data preprocessing and normalization
Fluorescent spot signals were obtained by subtracting
background intensity from the total spot intensity. The
genes with missing values for more than one of the exper-
iments were removed for further analysis. The variation
from the different labeling efficiencies was corrected using
within-slide global normalization, which subtracted the
median of log2 (R/G) intensity ratio from the log2 trans-
formed data.
Analysis of Microarray-CGH
The obtained data were analyzed using the Chromosome
Analyzer and Map Viewer using S-plus (CAMVS) devel-
oped by the Cancer Metastasis Research Center (CMRC),
Yonsei University College of Medicine, Seoul, Korea. To
evaluate the general genetic pattern of whole chromo-
some, 0.025 span was introduced to give the weighted
mean through the neighboring 250 probes, resulting in
the advantage of evaluation of ratios of 250 proves simul-
taneously. Smoothing line is based on the more weight on
the nearer probes. In this study, we used the predeter-
mined cut-off value for the significant copy changes by
comparing the level of genetic changes using normal tis-
sue DNAs including placenta, lymphocyte and gastric tis-
sues in the previous study [32]. Based on the assumption
that the sex chromosomal single copy difference is the
only change between the XX and XY normal gastric tissue
DNA, the result showed that the changes in the autosomal
chromosomes were minimal with the range of -0.3 <
log2(R/G) < 0.3 (mean ± 1SD), while the changes in the
sex chromosomes were -0.64 < log2(R/G)< 0.64. Hence,
cut-off values of log2(R/G) > ± 0.64 (mean ± 1SD) as
amplification or deletion, log2(R/G)> ± 0.3 (mean ± 1SD)
as gain or loss were determined.
The Significant Analysis of Microarray (SAM) was used to
identify the specific genes that showed differences
between the groups [23] with more than 15% frequenciesBMC Genomics 2007, 8:305 http://www.biomedcentral.com/1471-2164/8/305
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in the group. To evaluate the accuracy of selected genes
representing the thymoma subtypes, we performed the
analysis by using Prediction Analysis of Microarray (PAM)
software [24]. The obtained data were clustered using soft-
ware program Cluster version 2.10 and visualized with
Treeview version 1.47 [38].
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